Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CPA1 | P15085 | 2/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPA3 | P15088 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.39 |
| ▸ | TET3 | O43151 | 1/20 | 0.39 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL11036519 | 0.92 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRALDH1A1CPA1CPB1 | |
| Styrene SCHEMBL4403563 | 0.84 | ALDH1A1 (0.47) | SMN1; SMN2TSHRALDH1A1CPA1CPB1 | |
| Malic Acid SCHEMBL28826571 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRALDH1A1KMOTET2 | |
| Malic Acid SCHEMBL5134812 | 0.84 | CASP1 (0.45) | SMN1; SMN2TSHRALDH1A1 | |
| Styrene SCHEMBL9189910 | 0.83 | ALDH1A1 (0.54) | SMN1; SMN2TSHRALDH1A1CYP2C19PAM | |
| Styrene SCHEMBL10982104 | 0.80 | ALDH1A1 (0.42) | SMN1; SMN2TSHRALDH1A1PAM | |
| Naphthalene SCHEMBL2936422 | 0.80 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRCPA1CPB1CPA3 | |
| Malic Acid SCHEMBL27794963 | 0.79 | SMN1; SMN2 (0.88) | SMN1; SMN2KMOTET2TET3TET1 | |
| Malic Acid SCHEMBL9771207 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1CYP2C19KMOPTGS2 | |
| Malic Acid SCHEMBL9771298 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1CYP2C19KMOPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023082193-A1 | METHOD FOR MODULATING TUMOR MICROENVIRONMENT TOWARD ANTI-CANCER PHENOTYPE IN A SUBJECT IN NEED THEREOF USING NANO-MODULATOR AND APPLICATIONS THEREOF | SHIEH, DAR-BIN (CN) | 2023-05-19 | — | — | WO | claimed |
| EP-2542223-B1 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2015-09-23 | — | — | EP | claimed |
| CN-102753156-B | Oral complex formulation comprising probiotic composition and 5-HT4 receptor agonist and method for preparing same | HANMI HOLDINGS Co.,Ltd. (KR) | 2014-10-08 | — | — | CN | claimed |
| EP-2542223-A2 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF | Hanmi Science Co., Ltd. (KR) | 2013-01-09 | — | — | EP | claimed |
| US-20120321709-A1 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2012-12-20 | — | — | US | claimed |
| CN-102753156-A | Oral complex formulation comprising probiotic composition and 5-HT4 receptor agonist and method for preparing same | HANMI HOLDINGS CO LTD | 2012-10-24 | — | — | CN | claimed |
| WO-2011108826-A2 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF | HANMI HOLDINGS CO., LTD. (KR) | 2011-09-09 | — | — | WO | claimed |
| EP-4747390-A2 | PROTEIN EXPRESSION REAGENTS | Nuclera Ltd (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20250372272-A1 | HIGH-POROSITY CERAMIC BURNABLE ABSORBERS | STANDARD NUCLEAR, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025109341-A1 | USE OF DNA ENCODED LIBRARIES | NUCLERA LTD (GB) | 2025-05-30 | — | — | WO | disclosed |
| US-20250146041-A1 | METHODS FOR CELL FREE PROTEIN SYNTHESIS AND POST TRANSLATIONAL MODIFICATION OF THE EXPRESSED PROTEINS | NUCLERA LTD (GB) | 2025-05-08 | — | — | US | disclosed |
| US-20250109226-A1 | NATIVE CELL MEMBRANE NANOPARTICLES | VIRGINIA COMMONWEALTH UNIVERSITY | 2025-04-03 | — | — | US | disclosed |
| WO-2025042377-A1 | HIGH-POROSITY CERAMIC BURNABLE ABSORBERS | Ultra Safe Nuclear Corporation (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-2542223-B1 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2015-09-23 | — | — | EP | disclosed |
| CN-102753156-B | Oral complex formulation comprising probiotic composition and 5-HT4 receptor agonist and method for preparing same | HANMI HOLDINGS Co.,Ltd. (KR) | 2014-10-08 | — | — | CN | disclosed |
| EP-2542223-A2 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF | Hanmi Science Co., Ltd. (KR) | 2013-01-09 | — | — | EP | disclosed |
| US-20120321709-A1 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2012-12-20 | — | — | US | disclosed |
| CN-102753156-A | Oral complex formulation comprising probiotic composition and 5-HT4 receptor agonist and method for preparing same | HANMI HOLDINGS CO LTD | 2012-10-24 | — | — | CN | disclosed |
| WO-2011108826-A2 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF | HANMI HOLDINGS CO., LTD. (KR) | 2011-09-09 | — | — | WO | disclosed |
| EP-0540016-A1 | Photosensitive resin and resin composition for lithographic printing | Nippon Paint Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109226-A1 | NATIVE CELL MEMBRANE NANOPARTICLES | CD63, LNPK, NUP210 | SMN1; SMN2 1664/4885TSHR 2384/4885ALDH1A1 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.